Zvrko Elvir, Mikic Anton, Vuckovic Ljiljana, Djukic Vojko, Knezevic Milan
Clinic for Otorhinolaryngology and Maxillofacial Surgery, Clinical Center of Montenegro, Podgorica, Montenegro.
Otolaryngol Head Neck Surg. 2009 Oct;141(4):478-83. doi: 10.1016/j.otohns.2009.07.001.
To examine immunohistochemical expression of CD105 among patients with laryngeal cancer and investigate the prognostic significance of CD105-assessed microvessel density (MVD).
Cross-sectional study.
University hospital.
The study comprised 80 patients with laryngeal squamous cell carcinoma who underwent complete excision. Clinicopathological data were collected retrospectively. Immunohistochemical analysis was performed with CD105 (endoglin) antibody. Positive-stained microvessels for CD105 were counted on hot spots of tumors at x200 magnification.
Average CD105-assessed MVD in considered laryngeal squamous cell carcinomas (SCCs) was 12.9 (SD 3.84). High expression of CD105 correlated significantly with advanced T (tumor) classification (P = 0.008), advanced TNM (tumor, node, metastasis) stage (P = 0.001), tumor recurrence (P = 0.001), and age > or =65 years (P = 0.026). The multivariate logistic regression showed that a high CD105+ MVD (odds ratio [OR] 4.27; P = 0.019) and advanced TNM stage (OR 3.72; P = 0.047) were independent markers of tumor recurrence. High MVD, advanced clinical stage, the presence of lymph node metastasis at the time of diagnosis, and age <66 years were associated with worse disease-free survival. Cox regression analysis revealed that expression of CD105 (P = 0.016) and advanced clinical stage (P = 0.05) were the independent factors for disease-free survival.
The present results suggest that MVD evaluation with CD105 is a promising prognostic factor for the outcome of patients with laryngeal SCC. CD105-assessed MVD could help to identify patients with more aggressive disease and increased risk of developing malignancy recurrence after treatment.
检测喉癌患者中CD105的免疫组化表达,并探讨通过CD105评估的微血管密度(MVD)的预后意义。
横断面研究。
大学医院。
本研究纳入80例行完整切除的喉鳞状细胞癌患者。回顾性收集临床病理资料。采用CD105(内皮糖蛋白)抗体进行免疫组化分析。在200倍放大倍数下,对肿瘤热点区域中CD105阳性染色的微血管进行计数。
在纳入的喉鳞状细胞癌(SCC)中,通过CD105评估的平均MVD为12.9(标准差3.84)。CD105的高表达与T(肿瘤)分期进展(P = 0.008)、TNM(肿瘤、淋巴结、转移)分期进展(P = 0.001)、肿瘤复发(P = 0.001)以及年龄≥65岁(P = 0.026)显著相关。多因素逻辑回归显示,高CD105 + MVD(比值比[OR] 4.27;P = 0.019)和TNM分期进展(OR 3.72;P = 0.047)是肿瘤复发的独立标志物。高MVD、临床分期进展、诊断时存在淋巴结转移以及年龄<66岁与无病生存期较差相关。Cox回归分析显示,CD105的表达(P = 0.016)和临床分期进展(P = 0.05)是无病生存期的独立因素。
目前的结果表明,用CD105评估MVD是喉SCC患者预后的一个有前景的预测因素。通过CD105评估的MVD有助于识别疾病侵袭性更强且治疗后发生恶性肿瘤复发风险增加的患者。